South African variant may cut response from Pfizer/BioNTech shot, study finds
pharmaphorum
FEBRUARY 18, 2021
The South African coronavirus variant may cut the effectiveness of Pfizer/BioNTech’s vaccine by around two thirds, according to a laboratory study. Mutations may alter neutralisation by affecting spike function rather than antigen response and its also unclear from this study how the T-cell response is affected.
Let's personalize your content